Drug Trial Radar · NCT02616562
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Mar 31, 2016
Primary completion
Sep 26, 2024
Study completion Sep 26, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 treatment compared to daily growth hormone treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children with growth hormone deficiency. The main trial period will consist of 26 weeks of treatment, followed by a 26 week extension period.
Conditions
- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
Interventions
somapacitanDrug
Administered subcutaneously (s.c., under the skin) once-weekly.
Norditropin® FlexPro® penDrug
Administered subcutaneously (s.c., under the skin) once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Height Velocity (HV) (cm/Year) During the First 26 Weeks of Treatment, Measured as Standing Height With StadiometerTime frame: Baseline (week 0), week 26
- Cohort II and Cohort III - Adverse Events Rate, Including Injection Site Reactions in Children With GHD.Time frame: From week 156 up to week 364
Locations
89 sites in 14 countries. Site status is shown where the registry gives one.
Children's of Alabama
Birmingham, Alabama
Children's Hospital Los Angeles - Endocrinology
Los Angeles, California
Mattel Children's Hospital at UCLA
Los Angeles, California
Valley Children's Hospital
Madera, California
Novo Nordisk Clinical Trial Call Center
San Diego, California
The Regents of the Univ of CA
San Diego, California
Rocky Mt Ped and Endo
Centennial, Colorado
Ped Endo Assoc PC-G.V
Greenwood Village, Colorado
Nemours/AI duPont Hosp-Chld
Wilmington, Delaware
The Endocrine Center
Pembroke Pines, Florida
Childrens Hospital of Chicago
Chicago, Illinois
Riley Hospital For Children
Indianapolis, Indiana
Novo Nordisk Clinical Trial Call Center
Minneapolis, Minnesota
University of Minnesota_Minneapolis_2
Minneapolis, Minnesota
Goryeb Children's Hospital
Morristown, New Jersey
Novo Nordisk Clinical Trial Call Center
Morristown, New Jersey
Rutgers-Rwjms
New Brunswick, New Jersey
UBMD Peds-Div of Endo/Diabetes
Buffalo, New York
Novo Nordisk Clinical Trial Call Center
Mineola, New York
NYU Langone Hospital-LI
Mineola, New York
CCHMC_Cinc
Cincinnati, Ohio
Novo Nordisk Clinical Trial Call Center
Cincinnati, Ohio
University Of Oklahoma-Tulsa
Tulsa, Oklahoma
Dell Pediatric Research Institute
Austin, Texas
Endocrine Associates Of Dallas
Plano, Texas
Children's Hsptl Of The Kings
Norfolk, Virginia
MultiCare Inst for Res & Innov
Tacoma, Washington
Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
Graz, Austria
Site not named
Graz, Austria
LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
Salzburg, Austria
LKH St. Poelten, Kinder-und Jugendheilkunde
Sankt Pölten, Austria
Landeskrankenhaus Villach
Villach, Austria
Salzkammergut-Klinikum Vöcklabruck
Vöcklabruck, Austria
Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
Linz, Upper Austria, Austria
UZ Brussel
Brussels, Belgium
Site not named
Brussels, Belgium
Cliniques Universitaires Saint-Luc - Serv. Pédiatrie
Brussels, Belgium
UZ Leuven - Kindergeneeskunde
Leuven, Belgium
CHU de Liège, site N.-D. des Bruyères
Liège, Belgium
Serviço de Endocrinologia e Metabologia do HC-UFPR
Curitiba, Paraná, Brazil
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.